Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report

Aakriti Arora; Jacob Zaemes; Metin Ozdemirli; Chul Kim

doi:10.3389/fonc.2023.1134151

Frontiers in Oncology (Mar 2023)

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report

Aakriti Arora,
Jacob Zaemes,
Metin Ozdemirli,
Chul Kim

Affiliations

Aakriti Arora: Department of Medicine, MedStar Washington Hospital Center, Washington, DC, United States
Jacob Zaemes: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States
Metin Ozdemirli: Department of Pathology, MedStar Georgetown University Hospital, Washington, DC, United States
Chul Kim: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States

DOI: https://doi.org/10.3389/fonc.2023.1134151
Journal volume & issue: Vol. 13

Abstract

Read online

Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a KIF5B–RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords